|
Male
|
22 (85%)
|
21 (72%)
|
0.34
|
|
Age
|
62.3 (5.7)
|
63.8 (6.7)
|
0.38
|
|
VO2peakffm (mL/kg ffm0.67/min)
|
124 (24)
|
126 (25)
|
0.83
|
|
VO2peakbw (mL/kg/min)
|
20.8 (4.9)
|
20.6 (5.0)
|
0.85
|
|
Body weight (kg)
|
96.2 (13.8)
|
95.5 (10.7)
|
0.85
|
|
Body mass index (kg/m2)
|
31.5 (29.6; 33.5)
|
31.3 (29.9; 33.7)
|
0.85
|
|
Body fat mass (kg)
|
32.6 (7.6)
|
34.6 (8.0)
|
0.36
|
|
Waist circumference (cm)
|
110 (10)
|
108 (7)
|
0.36
|
|
Hip circumference (cm)
|
111 (8)
|
110 (7)
|
0.80
|
|
Systolic blood pressure (mmHg)
|
126 (13)
|
127 (15)
|
0.78
|
|
Diastolic blood pressure (mmHg)
|
74 (9.2)
|
71 (7.7)
|
0.18
|
|
Total cholesterol (mmol/L)
|
4.3 (0.8)
|
4.1 (0.7)
|
0.23
|
|
Left ventricular ejection fraction (%)
|
53 (8)
|
53 (7)
|
0.97
|
|
Pre-diabetes
|
21 (81%)
|
25 (86%)
|
0.59
|
|
Ischaemic aetiology and treatment
|
|
Myocardial infarction
|
8 (31%)
|
22 (76%)
|
< 0.001
|
|
Percutaneous coronary intervention
|
17 (65%)
|
23 (79%)
|
0.25
|
|
Coronary artery bypass graft
|
6 (23%)
|
6 (21%)
|
0.83
|
|
Prior cardiac rehabilitation
|
24 (92%)
|
21 (72%)
|
0.06
|
|
CCS-class
|
|
0
|
21 (81%)
|
23 (79%)
| |
|
I
|
5 (19%)
|
6 (21%)
|
0.89
|
|
NYHA-class
|
|
I
|
21 (81%)
|
21 (72%)
| |
|
II
|
5 (19%)
|
7 (24%)
|
0.87
|
|
III
|
0 (0%)
|
1 (3%)
| |
|
Medication
|
|
ACE-I/ARB
|
15 (58%)
|
21 (72%)
|
0.57
|
|
Acetylsalicylic acid
|
23 (88%)
|
26 (90%)
|
1.00
|
|
Beta blocker
|
12 (46%)
|
16 (55%)
|
0.50
|
|
Calcium antagonist
|
6 (23%)
|
10 (34%)
|
0.39
|
|
Statin
|
25 (96%)
|
28 (97%)
|
1.00
|
|
Other cholesterol-lowering drug
|
5 (19%)
|
2 (7%)
|
0.24
|
